TGFβ1-IN-1

CAS No. 2348795-14-0

TGFβ1-IN-1( —— )

Catalog No. M35554 CAS No. 2348795-14-0

TGFβ1-IN-1 is an orally active TGF-β1 inhibitor that inhibits the production of TGF-β1-induced fibrotic markers (α-SMA and fibronectin) and can be used for the study of cancer and autoimmune diseases.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    TGFβ1-IN-1
  • Note
    Research use only, not for human use.
  • Brief Description
    TGFβ1-IN-1 is an orally active TGF-β1 inhibitor that inhibits the production of TGF-β1-induced fibrotic markers (α-SMA and fibronectin) and can be used for the study of cancer and autoimmune diseases.
  • Description
    TGFβ1-IN-1 (compound 42) is a potent, orally active TGF-β1 inhibitor. TGFβ1-IN-1 inhibits the upregulation of TGF-β1-induced fibrosis markers (α-SMA and fibronectin) and can be used in liver fibrosis disease studies.
  • In Vitro
    TGFβ1-IN-1 (compound 42) (0-20 μM, 72 h) inhibits the proliferation of TGF-β1 (5 ng/mL)-treated LX- 2 cells and inhibits LO2 cell viability with an IC 50 of 105 μM.Cell Viability Assay Cell Line:HSCs (LX-2) cells Concentration:20 μM Incubation Time:24 or 72 hours Result:Showed the survival rate of 77.5% and the inhibition rate of 30.3% for LX-2 cells.Significantly inhibited fibronectin and α-SMA protein expression.
  • In Vivo
    TGFβ1-IN-1 (compound 42) (p.o., 15 or 30 mg/kg, daily, 3weeks) prevents CCl4-induced liver injury and fibrosis, inhibits the activation of hepatic stellate cell (HSC) and epithelial-mesenchymal transition (EMT), and improves the immune microenvironment of CCl4-induced liver fibrosis as well as CCl4-induced systemic toxicity in C57BL/6J mice.Animal Model:Liver fibrosis C57BL/6J mice induced by CCl4 Dosage:15 or 30 mg/kg Administration: Oral administration; daily; 3 weeks Result:Significantly prevented CCl4-induced liver injury and reduced liver weight factor, serum ALT, AST, CHO and TG levels.Significantly improved structural damage and inflammatory cell infiltration in the liver, and reduced collagen deposition in liver tissue.Reduced accumulation of CCl4-induced immune cells, such as hepatic macrophages (F4/80+ CD11b+), Th1 cells (CD69+ CD4+), and Th2 cells (CD69+ CD8+) so on.
  • Synonyms
    ——
  • Pathway
    Others
  • Target
    Other Targets
  • Recptor
    TGF-beta/Smad
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    2348795-14-0
  • Formula Weight
    364.438
  • Molecular Formula
    C22H24N2O3
  • Purity
    >98% (HPLC)
  • Solubility
    In Vitro:?DMSO : 100 mg/mL (274.39 mM; Ultrasonic )
  • SMILES
    O=C(C=CC1=CC=C(OC)C=C1)NC2=CC=CC(=C2)C(=O)NC3CCCC3
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Lin Yue, et al. Discovery and evaluation of phenacrylanilide derivatives as novel potential anti-liver fibrosis agents. Eur J Med Chem. 2022 Nov 15;242:114685.?
molnova catalog
related products
  • BAY-091

    BAY-091 is a novel, potent, and highly selective inhibitor of PIP4K2A kinase.

  • SMA-12b

    SMA-12b is an analog of the immunomodulatory parasite product ES-62 that has immunomodulatory activity, can modify the expression of many inflammatory response genes.

  • Dazolicin HCl

    Dazolicin HCl (Dazolicine HCl) is an orally available antiarrhythmic compound.